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Background: Exercise training (ET) in addition to optimal medical therapy (OMT) in patients with stable coronary
artery disease (CAD) has been demonstrated to be superior to percutaneous coronary interventions (PCI) with
respect to the composite endpoint of death, myocardial infarction, stroke, revascularization and hospitalization due
to worsening of angina. One mechanism leading to this superiority discussed in the literature is the increase in
coronary collateral blood flow due to ET. Until now, data demonstrating the positive effect of ET on the collateral
blood flow and the functional capacity of the coronary collateral circulation are still lacking.
Methods/design: The EXCITE trial is a three-armed randomized, prospective, single-center, open-label, controlled
study enrolling 60 patients with stable CAD and at least one significant coronary stenosis (fractional flow reserve
≤0.75). The study is designed to compare the influence and efficacy of two different 4-week ET programs [high-
intensity interval trainings (IT) versus moderate-intensity exercise training (MT) in addition to OMT] versus OMT only
on collateral blood flow (CBF). The primary efficacy endpoint is the change of the CBF of the target vessel after
4 weeks as assessed by coronary catheterization with a pressure wire during interruption of the antegrade flow of
the target vessel by balloon occlusion. Secondary endpoints include the change in plaque composition as assessed
by intravascular ultrasound (IVUS) after 4 weeks, myocardial perfusion as analyzed in MRI after 4 weeks and
12 months, peak oxygen uptake (V02 peak), change in endothelial function and biomarkers after 4 weeks, 3, 6 and
12 months. The safety endpoint addresses major adverse cardiovascular events (death from cardiovascular cause,
myocardial infarction, stroke, TIA, target vessel revascularization or hospitalization) after 12 months.
Discussion: The trial investigates whether ET for 4 weeks increases the CBF in patients with significant CAD
compared to a sedentary control group. It also examines the impact of two intensities of ET on the CBF as well as
the histological plaque composition. The trial started recruitment in June 2009 and will complete recruitment until
June 2012. First results are expected in December 2012 (4-week follow-up), final results (12-month long-term
secondary endpoint) in December 2013.
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Coronary artery disease (CAD) still remains one of the
leading causes of mortality in many countries with more
than 17 million deaths worldwide (WHO 2008). CAD is a
result of atherosclerosis, which has been interpreted to be
due to endothelial dysfunction and inflammatory reaction
[1,2]. Percutaneous coronary interventions (PCI) have been
shown to be favorable with respect to major cardiac events
in patients with acute coronary syndromes [3,4]. In patients
with stable CAD, the benefits of coronary revascularization
are less clear. In particular, there is no reported advantage
with respect to major cardiovascular events and mortality
compared to medical therapy only in patients with stable
angina [5-10].
Several randomized trials compared PCI in addition to
an optimal medical therapy (OMT) versus OMT only in
patients with stable CAD. The COURAGE trial is the lar-
gest randomized study comparing an OMT only with a
PCI plus OMT in patients with stable CAD. This mile-
stone trial showed comparable efficacy between the two
strategies with regard to a combined endpoint of death,
myocardial infarction and stroke [11-16].
In contrast, Kastrati and co-workers published a meta-
analysis of 17 randomized trials comparing OMT with a
PCI-based invasive strategy in 7,513 patients with stable
CAD and symptoms or signs of myocardial ischemia [17].
The major finding of this analysis was that PCI may im-
prove patients’ long-term survival compared to OMT with
a 20% reduction of the primary endpoint of all-cause death
in the PCI group. However, of all the trials included, three
also enrolled unstable patients presenting with acute cor-
onary syndrome (DANAMI, TIME, SWISSI II).
Since the first description of the coronary collateral
circulation by Blumgart et al. in 1948 [18], extensive
investigations have been done to quantify the coronary
circulation as well as to assess its anatomical contribu-
tion and functional capacity [19]. Berry and co-workers
[20] reported the presence of coronary collateral anasto-
moses to be a prognostically important adaption in
patients with CAD.
Seiler et al. [21] demonstrated reduced long-term mor-
tality in patients with stable CAD and well-developed
coronary collateral circulation. Moreover, in patients
with acute ST elevation myocardial infarction, extensive
collateral flow before reperfusion has been shown to be
a predictor for a favorable long-term outcome [22].Exercise training and CAD
Physical activity has been well documented to reduce
the cardiovascular event rate in a long-term perspective
[23,24]. In particular, Myers and co-workers reported a
strong inverse and graded reduction of mortality in
healthy subjects and patients with known CAD with
increased physical fitness [25,26].
As previously reported in a randomized trial enrolling
101 male participants, a combination of exercise training
(ET) and OMT in patients with stable CAD was asso-
ciated with a higher event-free survival and an increased
maximal oxygen-uptake as compared to PCI+OMT after
1 year of treatment [27]. Several mechanisms are reported
to be responsible for the improvement in event-free sur-
vival after ET. Besides a reduction of cardiovascular risk
factors, an improvement of endothelial function was docu-
mented after 4 weeks of ET [28]. An increase of coronary
collaterals was often hypothesized, but to date there are
no prospective studies available demonstrating a beneficial
effect of a specific therapy on the number of pre-existing
coronary collaterals or an induction of angiogenesis of col-
lateral vessels in human beings. However, currently no
clear consensus exists about how the best physiological
adaption can be achieved with different ET modalities
regarding the coronary collateral blood flow (CBF) [inter-
val training (IT) versus moderate-intensity continuous ex-
ercise training (MT)]. In a recently published review, a
strategy of IT alone or in combination with resistance
training resulted in significantly greater effects on cardior-
espiratory fitness and endothelial function compared to
MT [29]. Hambrecht et al. reported a regression of coron-
ary lesions only in patients performing regular physical ex-
ercise 5–6 h/week expending an average of 2,200 kcal/
week [30].
Assessment of the collateral blood flow
In the past, there has been growing interest in investigating
coronary collateralization [31,32], and several methods
have been used to assess the CBF (angiographic guidance
versus hemodynamic evaluation).
In 1995, Niebauer and co-workers published a rando-
mized study comparing intensive exercise training of
>3 h/week in addition to a low-fat diet with a sedentary
control group in regard to the change of the collateral
formation [33]. After 1 year, the study failed to show a
difference in collateral blood supply between the two
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graphic evaluation of collateral vessels based only on
QCA analysis.
In the 1990s, the method of measuring the fractional
flow reserve (FFR) as an invasive pressure-derived index
was reported by Pijls and De Bruyne [34,35]. This method
allows a measurement of the pressure distal to a coronary
stenosis.
Animal studies in healthy dogs [36,37] showed a signifi-
cant increase in CBF in those who underwent treadmill
training (75 min/day, 5 days/week) for 12 weeks. Beside a
quantitative increase of collateral vessels, a growth of the
diameter of epicardial collaterals was reported.
Compared to angiography-based QCA, measurement of
the CBF after an artificial vessel occlusion with a coronary
pressure wire seems to be a more functional approach to
assess collateral vessels. This method was first described
by Pijls et al. [35] as a quantitative assessment of recruit-
able CBF in human beings. In 120 consecutive patients
undergoing elective coronary angiography, an invasive
measurement of the mean arterial pressure (Pao), coronary
wedge pressure and central venous pressure (CVP) was
performed at balloon inflations of 2 min (Pocclusion). As
described by Zbinden et al., the coronary flow index (CFI)
is calculated as follows: Pocclusion  CVPð Þ= Pao  CVPð Þ
[38]. Zbinden and co-workers have demonstrated an in-
crease of the collateral flow index of normal and stenotic
vessels after 3 months of endurance training [35,38]. After
PCI of the target vessel, a measurement of the CBF with a
pressure wire under vessel occlusion with a balloon was
performed. After successful PCI without residual stenosis,
patients participated in an exercise program for up to
3 months three times a week. After 3 months, the preven-
tion of existing collateral vessels after PCI with ET was
reported. However, some limitations of the study need to
be addressed. First, because of its non-randomized study
design, a selection bias cannot be ruled out. Second, the
initial coronary stenosis leading to angina and cardiac
catheterization was treated by PCI before starting the ET
program. By treating the stenosis, the ischemic trigger to
increase angiogenesis might be reduced. This is partially
explained by a reported increase of VEGF levels and circu-
lating progenitor cells and an enhanced integration of
EPCs into the endothelial cell layer after performing a 4-
week ischemic ET program [39]. The authors did not report
in how many patients a bare metal stent or a drug-eluting
stent was implanted. This issue might have been important
considering the initial worsening of endothelial function of
PCI with a drug-eluting stent.
Buschmann et al. recently published a study analyzing
the impact of treatment with external counterpulsation on
the fractional flow reserve, and they reported a stimulation
of coronary angiogenesis in patients with stable CAD after
treatment with external counterpulsation for 7 weeks [40].Again, the non-randomized study design and the lack of a
real sham-group are limiting factors of the study.
Meier at al. [41] published a meta-analysis enrolling
6,529 subjects exploring the impact of coronary collaterals
on mortality. It has been shown that the presence of high
coronary collateralization indicates a 36% reduced mortal-
ity risk. The same research group reported a significantly
reduced 10-year survival rate in patients with low CBF
(CBF <0.25) compared to those with a well-developed col-
lateral circulation (CBF ≥0.25) [42].
Pohl and co-workers [43] investigated the effect of dy-
namic handgrip exercise on the collateral blood flow in
acute coronary occlusions. They found a significant in-
crease of the CBF in patients undergoing PCI performing
physical exercise for 3 min compared to a sedentary con-
trol group. The CBF was measured at the start and end of
two 1-min coronary occlusions.
In addition, Wustmann et al. [44] elucidated the CBF in
normal coronary arteries without stenotic lesions. They
reported an immediately recruitable CBF that is sufficient
to prevent myocardial ischemia during coronary balloon
occlusion in 20% of patients without coronary stenosis.
Currently, little is known about the direct effect of phys-
ical exercise training on collateral formation, and the prog-
nostic relevance of the CBF is still discussed controversially.
Currently, there is no adequately powered clinical trial to
assess the effect of different modalities of exercise training
on the CBF (high-intensity IT versus MT) in addition to an
OMT.
Hypothesis
Therefore, the Leipzig EXerCIse Training versus MEdical
Management (EXCITE) trial is designed to test the hy-
pothesis that a 4-week ET therapy in addition to OMT
can increase coronary CBF compared to baseline mea-
surements. In a second step analysis, the impact of dif-
ferent ET intensities (IT versus MT) on the change of
CBF will be elucidated.
Methods/design
Study objectives
The EXCITE study is a three-armed, randomized, pro-
spective, open-label, controlled trial in patients with
stable CAD and a significant coronary artery stenosis of
at least one major epicardial vessel. The severity of the
coronary stenosis is assessed by measurement of the
FFR. An FFR of ≤0.75 of at least one coronary stenosis
is feasible for study inclusion. The aim of the study is to
investigate the efficacy of 4 weeks of intensive exercise
training in addition to OMT on the amount of CBF
compared to a sedentary control group with OMT only.
It will determine if exercise training is superior to
standard medical therapy in increasing the CBF. More-
over, the Excite trial wants to demonstrate the
Table 2 Inclusion criteria
Inclusion criteria
1. Age >18 and <76 years
2. Stable angina pectoris CCS 1-3
3. Luminal stenosis of ≥50% in at least one major epicardial vessel
eligible for PCI
4. FFR ≤0.75 in the target vessel
5. Angina threshold ≥50 W
6. Patients have to sign the informed consent form
Table 3 Exclusion criteria
Exclusion criteria
1. Left main coronary artery stenosis >50%
2. High-grade stenosis (>75%) of the proximal left anterior descending
artery
3. Stenosis with a minimum diameter of <2 mm
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training compared to moderate-intensity exercise train-
ing. The trial is a proof-of-concept study and registered
under www.clinicaltrial.gov: NCT01209637.
Primary and secondary outcomes
The primary study endpoint of the EXCITE trial is the
change in the coronary CBF index after 4 weeks of ther-
apy among the three treatment groups (Table 1).
The secondary endpoints include the change in the tis-
sue composition of the target lesion after 4 weeks of exer-
cise training compared to optimal medical therapy only.
Other secondary endpoints are displayed in Table 1. To
confirm a potential advantage by long-term follow-up, a
12-month follow-up will be performed in the course of
the secondary endpoint evaluation.
Safety assessment includes bleeding complications
related to the invasive measurement of the CBF accord-
ing to the GUSTO criteria [45], stroke and renal failure.
Patient population
The study population will consist of 60 patients with stable
significant CAD enrolled at the University of Leipzig Heart
Centre, Leipzig, Germany.
Patients are eligible if they are >18 and ≤75 years of
age and have a significant coronary artery stenosis with
a FFR ≤0.75 in at least one coronary artery.
The exclusion criteria reflect known contraindications
for exercise training or application of adenosine. Eligible
patients have to present with stable angina for at least
8 weeks and need to have ≥1 focal coronary luminal sten-
osis of more than 50% eligible for PCI. All patients have to
be able to perform an ET program with a threshold of at
least 50 Watts (W) without angina pectoris or signs of is-
chemia. Inclusion and exclusion criteria are demonstrated
in Tables 2 and 3. Patients have to express willingness to
participate in the study for 12 months. Patients presenting
with a history of acute coronary syndromes within the pastTable 1 Primary and secondary endpoints
Primary Change in CBI after 4 weeks of treatment
Secondary 1. Change in plaque morphology by virtual
histology at 4 weeks as assessed by IVUS
2. Change in myocardial perfusion at 4 weeks and
12 months as assessed by adenosine MRI
3. MACE at 1, 3, 6 and 12 months
4. Hospitalization due to cardiovascular causes
5. Change in atherosclerotic parameters (hs-CRP,
ADMA, endostatin, EPC, ox LDL, cytokines,
adiponectine), lipid status and glucose status
6. Change in exercise capacity (ergospirometry) and
V02 peak2 months, significant valve disease, an LV ejection fraction
of ≤40% or contraindications to adenosine stress are not
eligible. In addition, patients with significant left main cor-
onary disease or an ostial lesion are excluded.
Study examinations
After the patient has provided written informed consent, a
cardiac catheterization with a clinical indication is per-
formed. In case of a coronary artery stenosis >50%, a
measurement of FFR will be performed. Only target ves-
sels that are feasible for PCI with a minimum diameter of
≥2 mm will be included. Therefore, patients with a coron-
ary stenosis of <2 mm will be excluded. Patients with an
FFR of ≤0.75 will be enrolled in the study and randomly
assigned by a computerized system in a 1:1:1 ratio to one
of the three treatment groups (20 patients per group) with
stratification according to age and sex. The study flow
chart is shown in Figure 1.4. Acute coronary syndromes or recent myocardial infarction within
the past 2 months
5. LV-EF ≤40%
6. Significant valvular heart disease
7. Pregnancy
8. Contraindication for application of adenosine:




9. Limitation of physical activity for reasons not due to coronary artery
disease
10. Life expectancy <1 year
11 Substance abuse (drug or alcohol) problem within the previous
6 months
FFR > 0.75 exclusionFFR ≤ 0.75
Measurement of collateral blood flow, IVUS 
Screening for eligibility 
Coronary artery stenosis of > 50% assessed by angiography
Informed consent
Measurement of the fractional flow reserve
60 patients undergo randomization
Interval training moderate training sedentary control group 
Baseline assessment: 
Clinical status, coronary catheterization with measurement of FFR and collateral blood flow, IVUS , 
ergospirometry, non-invasive measurement of the endothelial function, blood sam ples,
Follow up after 4 weeks: 
Clinical status, coronary catheterization with measurement of FFR and collateral blood 
flow, IVUS , ergospirometry, non-invasive measurement of the endothelial function, 
Follow up after 3 and 6 months:
Clinical status, ergospirometry, non-invasive measurement of the endothelial function, 
blood samples, echocardiography 
Follow up after 12 months:
Clinical status, ergospirometry, non-invasive measurement of the endothelial function, 
blood samples, echocardiography, MRI 
Figure 1 Study flow chart.
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Coronary angiography will be performed with 6-French
catheters at baseline and after the 4-week intervention. The
FFR is the maximal achievable flow, which determines the
functional capacity. The FFR is defined as the mean distalcoronary pressure divided by the mean proximal coronary
or aortic pressure during maximal hyperemia [46-48]. The
measurements will be performed using a coronary pressure
guide wire (Prime Wire, Volcano Corp., Rancho Cardova,
CA, USA, or Radi Pressure Wire Certus, St. Jude Medical,
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venous application of adenosine, administered via a right
femoral vein in dose of 140 μg/kg body weight/min.
Measurement of the FFR will be done after application
of adenosine infusion for approximately 2 min when a
steady state has been reached. Right atrial pressure will
be measured via the femoral vein in a standard manner.
Measurement of the coronary collateral circulation
The primary study endpoint (change in CBF) will be
assessed by sensor-tipped guide wires during vessel occlu-
sion with a balloon catheter for 1 min.
Therefore, a standard PCI balloon with a diameter
0.5 mm larger than the diameter of the target vessel is
delivered via the FFR guide wire and will be inflated prox-
imal to the coronary lesion within an angiographic healthy
coronary segment with a low pressure of 4–6 atm to inter-
rupt antegrade blood flow of the vessel during maximal
hyperemia. Contrast dye is injected to show the interrup-
tion of the antegrade blood flow. During the measure-
ment, the blood pressure of the target vessel distal to the
coronary stenosis is continuously monitored as well as the
systemic blood pressure.
To differentiate if the results after 4 weeks of therapy
are due to CAD or physiological adaptations, the same
measurements will be performed in a coronary vessel
free of coronary stenosis (the reference vessel).
After 4 weeks of treatment, measurements will be
repeated in the same coronary segments.
Cardiac catheterization as well as measurement of the
CBF will be performed by three very experienced invasive
cardiologists with expertise in hemodynamic analysis.
Nevertheless, the procedure may carry some risks such as
dissections of the coronary artery by the pressure wire, de-
velopment of the thrombus burden, stroke or myocardial
infarction during vessel occlusion. Application of adeno-
sine intravenously can result in a complete atrioventricular
block with short asystole.
Assessment of clinical symptoms and patient treatment
All patients undergo detailed assessment of medical his-
tory as well as physical examination at baseline and after
1, 3, 6 and 12 months. In patients without known diabetes,
an oral glucose tolerance test will be performed before
inclusion.
At baseline, 1, 3, 6 and 12 months, the angina pectoris
status will be documented according to CCS class 1–4 by
a physician blinded to the treatment group. In addition, a
symptom-limited bicycle ergospirometry and an echocar-
diography will be conducted.
An OMT is adjusted according to current clinical
practice guidelines in each group at least 2 weeks before
initial measurements were obtained. Statins, ß blockers,
angiotensin-converting enzyme inhibitors or angiotensin-1antagonists are obligatory. In addition, patients are treated
with an antiplatelet therapy with aspirin 100 mg daily or, if
the patient has undergone a previous PCI, a dual antipla-
telet therapy will be administered according to current
guidelines.
All patients enrolled in the study will be followed for
12 months. At any time during the study period, each pa-
tient can withdraw the informed consent. A patient with
signs of clinically worsening symptoms will be thoroughly
evaluated by the investigator, and if clinically indicated a
PCI will be performed. In patients presenting with an
acute coronary syndrome, a coronary angiography will be
performed immediately, and the target lesion will be trea-
ted by PCI. The study will be discontinued for a given pa-
tient if continuing would result in a significant safety risk.
Qualitative Comparative Analysis (QCA Analysis)
QCA measurements of the target lesion and the healthy
reference coronary artery will be obtained at baseline and
after 4 weeks respectively by two independent operators
using the Medis Software (Medis Medical Imaging Systems,
QAngio XA, version 7.2).
The following parameters will be measured: lesion
lengths (mm), minimum/maximum lumen diameter (mm),
target stenosis (%) and the diameter of the reference coron-
ary artery at the location of FFR measurement (mm).
Intravascular ultrasound examination (IVUS sub-study)
IVUS imaging with an analysis of the virtual histology of
the coronary plaque has the potential to overt possible
effects of the specific therapy of the study with respect
to change in the plaque composition and plaque volume
of the target lesion.
Therefore, an IVUS with virtual histology analysis will
be performed at baseline and after 4 weeks of therapy.
After measurement of the FFR and CBI, an Eagle EyeR
Gold Intravascular Ultrasound Imaging Catheter (Volcano
Corporation, Rancho Cardova, CA, USA) will be inserted
distal to the target lesion at a landmark side branch and
pulled back via a motorized transducer pullback device for
a length of at least 4 cm. ECG-triggered virtual histology is
performed to analyze the tissue composition.
The details on IVUS image acquisition and analysis have
been reported previously [49-53]. The percentage of ather-
oma volume, total plaque burden, minimal lumen area
(mm2), lesion lengths (mm) and differentiation of plaque
tissue (%) will be measured [54].
Adenosine MR perfusion imaging (MRI sub-study)
A cine MRI and an adenosine perfusion MR will be per-
formed at baseline, 4 weeks and 12 months. The aim of
this sub-study is to investigate whether MR perfusion im-
aging can predict myocardial perfusion defects, collateral
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ercise training compared to a sedentary control group.
Imaging will be performed with a 1.5-T scanner (Philips
Intera CV, Best, The Netherlands) in a standard fashion.
After 4 min of adenosine infusion, a perfusion sequence
will be started according to a standard protocol. All mea-
surements will be performed by blinded operators with ex-
cellent intra- and interobserver variabilities and excellent
reproducibility. Exclusion criteria for the MRI sub-study
are (1) severe claustrophobia, (2) implantable pacemaker
and defibrillator, and (3) contraindications for adenosine
(first and second degree AV block, sick sinus syndrome,
long QT syndrome, asthma bronchiale).
Exercise testing
All patients will perform a cardiopulmonary exercise test on
a bicycle ergospirometer (Ergoline, Bitz, Germany) to deter-
mine the individual exercise capacity and the peak oxygen
uptake (V02 peak), angina threshold and ischemic threshold.
The step protocol starts at 25 W and increases by steps of
25 W every 3 min. The Zan SpiroErgo 600 (Zan, Winkling,
Austria) is used to measure breath-by-breath gas exchange
levels of ventilation (E), oxygen uptake and carbon dioxide
production (CO2). Important measured parameters are the
exercise capacity (Watts), angina pectoris threshold, is-
chemic threshold, V02 max/peak, time to discontinuation
(T max) and time to anaerobic threshold (T RQ1). After
4 weeks, 3, 6 and 12 months, the test will be repeated.
Exercise training program
Patients randomized in the IT group perform exercise
training under supervision by experienced physicians
and exercise physiologists four times daily for 30 min,
five times a week for a total of 4 weeks. The training
program is intended to be a high-intensity training with
partial IT up to 95% of the individual ischemia-/angina-
free exercise capacity.
Patients randomized in the MT group will undergo a
multimodal lifestyle intervention in a specialized hospita-
lized rehabilitation unit. These patients will exercise 6–8
sessions per day (20 min each) under close medical super-
vision at a maximum level of 70% of their individual
angina-/ischemia-free exercise threshold. Additionally,
they will be in lifestyle modification as well as individual
physiotherapeutic therapies.
Patients assigned to the sedentary control group receive
an OMT and are encouraged to carry out regular ET
according to current guidelines (2–3 sessions per week,
20–30 min each). They are supervised by their general
practitioner.
Laboratory values and biomarkers
Blood samples will be taken and analyzed at baseline, at
1, 3, 6 and 12 months. Routine measurements of lipidand glucose metabolism will be performed. In addition,
the amount of circulating endothelial progenitor cells
(EPCs) will be quantified by flow cytometry as recently
described [55,56].
Asymmetric dimethylarginine (ADMA) and endostatin
will be measured using a commercial available ELISA kit
(for ADMA: Immundiagnostik AG, Bensheim, Germany;
for Endostatin: Antigenix American Incorporation) fol-
lowing the manufacturer’s instructions.
The association between interleukin-6 and tumor ne-
crosis factor-alpha to the CBF will be determined.
Long-term follow-up
Follow-up will be conducted after 3, 6 and 12 months as
ambulatory visits at our institution. In case of any
events, these will be verified by hospital charts or direct
contact with the treating physician.
Data and statistical analysis
In the absence of randomized trials and lacking data
regarding ET and its impact on the collateral blood sup-
ply, a power calculation was not possible. Therefore, the
Excite trial is designed to be a proof-of-concept study.
Categorical variables are presented as frequencies and
percentages, continuous variables as means and standard
deviations (SD), or medians and interquartile ranges for
variables with skewed distributions. The primary endpoint
will be analyzed according to the intention-to-treat
principle using the Kruskal-Wallis test. In addition, event
rates in all of these three treatment arms will be estimated
(95%CI), and the time-to-event rates will be described
using the Kaplan-Meier method. The secondary endpoints
(Table 3) will be analyzed by appropriate methods accord-
ing to data type to compare the three treatment arms. If
statistically possible, pre-defined subgroup analyses will be
performed including patients’ gender, presence of diabetes,
amount of pre-existing CBF and FFR of the target lesion
at baseline.
Discussion
The EXCITE trial protocol is focused on patients un-
dergoing cardiac catheterization with stable CAD and
hemodynamically significant coronary artery stenosis.
According to previous data, there is still uncertainty
whether ET increases the coronary collateral circulation.
One critical point of previous studies is the angiographic
evaluation of collateral vessels only. Therefore, the inva-
sive measurement of the FFR-based CBF is a functional
approach with higher accuracy to assess collateral vessels.
This might help to differentiate even small effects of the
several therapies. So far, FFR-based evaluation of CBF has
only been reported in non-randomized trials.
The EXCITE trial is designed as an all-comers study
without specific subgroup exclusion in order to receive
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defined several subgroups.
Nevertheless, within this study two different training pro-
grams can be compared with a sedentary control group.
This might help to find the most effective training program
in patients with stable angina pectoris and significant cor-
onary stenosis. Because of the lack of previous data investi-
gating the CBF, the present study was designed as a proof-
of-concept-trial. Therefore, a valid power calculation was
not possible.
Blinding to avoid bias might have been beneficial.
However, we implemented methods to reduce bias, such
as the use of a central computerized randomization sys-
tem and a blinded MRI and IVUS core laboratory.
To the best of our knowledge, this is the first rando-
mized study comparing the CBF in patients after high-
and moderate-intensity 4-week physical exercise training
programs compared to OMT only.
Conclusion
Exercise training results in an increased delivery of
blood to myocardial regions in need, but the pathophysi-
ology is still unclear.
The Excite trial was designed to investigate whether in-
tensive exercise training for 4 weeks as IT and MT in com-
parison to a sedentary control group with OMT only will
increase the coronary collateral circulation in patients with
stable CAD and significant epicardial stenosis (FFR≤0.75).
Trial status
Recruitment has commenced in June 2009. We expect to
complete recruitment by June 2012. Final results (12-months
clinical endpoint) are planned to be published in July 2013.
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